Synaptogenix (NASDAQ:TAOX) Stock Rating Lowered by Wall Street Zen

Synaptogenix (NASDAQ:TAOX) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Synaptogenix in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of “Sell”.

Synaptogenix Stock Performance

TAOX stock opened at $5.70 on Friday. The stock has a market cap of $42.59 million, a P/E ratio of -0.28 and a beta of 1.68. Synaptogenix has a twelve month low of $1.84 and a twelve month high of $11.98. The company’s 50 day moving average is $4.71 and its two-hundred day moving average is $5.82.

Synaptogenix (NASDAQ:TAOX) last issued its earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. The company had revenue of ($2.46) million during the quarter.

Synaptogenix Company Profile

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University.